Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study.

Teitelbaum JE, Johnson C, St Cyr J.

J Altern Complement Med. 2006 Nov;12(9):857-62.

PMID:
17109576
2.

A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome.

Morris G, Maes M.

Metab Brain Dis. 2013 Dec;28(4):523-40. doi: 10.1007/s11011-012-9324-8. Epub 2012 Jun 21. Review.

PMID:
22718491
5.

Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review.

Alraek T, Lee MS, Choi TY, Cao H, Liu J.

BMC Complement Altern Med. 2011 Oct 7;11:87. doi: 10.1186/1472-6882-11-87. Review.

6.

Chronic fatigue syndrome: diagnosis and treatment.

Yancey JR, Thomas SM.

Am Fam Physician. 2012 Oct 15;86(8):741-6. Review.

7.

Small heart syndrome in patients with chronic fatigue syndrome.

Miwa K, Fujita M.

Clin Cardiol. 2008 Jul;31(7):328-33. doi: 10.1002/clc.20227.

9.
10.

Cytotoxic lymphocyte microRNAs as prospective biomarkers for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.

Brenu EW, Ashton KJ, van Driel M, Staines DR, Peterson D, Atkinson GM, Marshall-Gradisnik SM.

J Affect Disord. 2012 Dec 10;141(2-3):261-9. doi: 10.1016/j.jad.2012.03.037. Epub 2012 May 8.

PMID:
22572093
11.

Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers.

Watt T, Oberfoell S, Balise R, Lunn MR, Kar AK, Merrihew L, Bhangoo MS, Montoya JG.

J Med Virol. 2012 Dec;84(12):1967-74. doi: 10.1002/jmv.23411.

12.
13.

Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.

Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, Næss H, Dahl O, Nyland H, Mella O.

PLoS One. 2011;6(10):e26358. doi: 10.1371/journal.pone.0026358. Epub 2011 Oct 19.

14.

Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.

Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT.

In Vivo. 2007 Sep-Oct;21(5):707-13.

15.

Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Booth NE, Myhill S, McLaren-Howard J.

Int J Clin Exp Med. 2012;5(3):208-20. Epub 2012 Jun 15.

16.

Immunological aspects of chronic fatigue syndrome.

Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G.

Autoimmun Rev. 2009 Feb;8(4):287-91. doi: 10.1016/j.autrev.2008.08.003. Epub 2008 Sep 16. Review.

PMID:
18801465
17.

Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults.

Chang CM, Warren JL, Engels EA.

Cancer. 2012 Dec 1;118(23):5929-36. doi: 10.1002/cncr.27612. Epub 2012 May 30.

18.

Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the 'single syndrome' hypothesis.

Abbi B, Natelson BH.

QJM. 2013 Jan;106(1):3-9. doi: 10.1093/qjmed/hcs156. Epub 2012 Aug 26. Review.

19.

Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome.

Plioplys AV, Plioplys S.

Neuropsychobiology. 1997;35(1):16-23.

PMID:
9018019

Supplemental Content

Support Center